Last reviewed · How we verify
A Phase III Trial to Determine the Efficacy of Bivalent AIDSVAX B/B Vaccine in Adults at Risk of Sexually Transmitted HIV-1 Infection in North America
The purpose of this study is to see if an HIV vaccine, AIDSVAX B/B, can protect adults who are at risk from becoming infected with HIV. Patients who become infected despite immunization will be studied to see if receiving the vaccine before becoming infected will help keep HIV levels (viral load) low.
Details
| Lead sponsor | VaxGen |
|---|---|
| Phase | Phase 3 |
| Status | COMPLETED |
| Enrolment | 5000 |
Conditions
- HIV Infections
- HIV Seronegativity
Interventions
- MN rgp120/HIV-1 and GNE8 rgp120/HIV-1
Countries
United States, Canada, Netherlands, Puerto Rico